Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
Prostate Cancer
DRUG: Degarelix
Plasma degarelix PK profile (blood sample analysis): measured by (Cmax, AUC, Tmax), Day 0-28 and at Day 112-140|Trough plasma levels (blood sample analysis), Actual levels prior to dosing, Day 28, 56, 84, 112, 140, 168 and 196
Proportion of patients with testosterone ≤0.5 ng/mL, From baseline to Day 196|Serum levels of testosterone and PSA, From baseline to Day 196|Percentage change in PSA levels, From baseline to Day 196|Changes in patient-reported injection site pain (VAS scores over time), Will compare starting dose to maintenance doses, At 5 minutes and at 60 minutes after each injection|Proportion of patients without clinically significant pain (VAS score of ≤10 mm), 60 minutes after each dosing injection|Incidence and severity of investigator-evaluated injection site reactions, From baseline to Day 196|Cumulative probabilities of suppressing testosterone to castrate level (≤0.5 ng/mL) by visit, From Day 28 onwards (up to Day 196)|Predictive one-year suppression rate and 95% CI: The cumulative probability of suppressing testosterone to castrate levels (≤0.5 ng/mL), From Day 28 to Day 364|Incidence of adverse events (AEs) examined by frequency, severity, seriousness and discontinuation from study due to AEs, From baseline to Day 196|Clinically significant changes in laboratory values, From baseline to Day 196|Clinically significant changes in ECGs, vital signs, physical examinations, and body weight, From baseline to Day 196
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.